[Skip to Navigation]
June 1961

Furaltadone: Antibacterial Activity in Vitro and in Serum of Patients During Treatment

Author Affiliations


From the Thorndike Memorial Laboratory, Second and Fourth (Harvard) Medical Services, Boston City Hospital and the Department of Medicine, Harvard Medical School. Dr. McCarthy's present address is Western Montana Clinic, Missoula, Mont.

Arch Intern Med. 1961;107(6):863-871. doi:10.1001/archinte.1961.03620060063008

The nitrofuran derivative now known by the generic name furaltadone and by the trade name Altafur (laboratory code NF-260) was first introduced in October, 1958, by Kefauver, Paberzs, and McNamara1 under the name "furmethonol" as a potentially useful agent for peroral treatment of systemic bacterial infections. Since that time there have appeared several papers dealing with its antibacterial action in vitro, particular attention being given to the susceptibility of nearly all strains of Staphylococcus aureus including those resistant to the most widely used antibiotics.2-9 In January, 1960, Christenson and Tracy10 published a review of 466 cases treated with this drug by various clinicians and collected by the Medical Department of Eaton Laboratories; of 483 infections diagnosed in these cases, 82% were listed as either cured or improved, and only 8% were listed as failures. About onehalf of all these patients were noted as having first failed to

Add or change institution